Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Raising $7M in Sale of Convertible Preferred Shares

NEW YORK (GenomeWeb News) – Transgenomic today said that it expects to raise $7 million in gross proceeds from the sale of 1,443,297 convertible preferred shares.

The Omaha, Neb.-based molecular diagnostics company said that it will sell the shares of Series B convertible preferred shares to affiliates of investment firm Third Security at $4.85 per share. The preferred shares will be convertible into common shares of Transgenomic on a one-for-one basis, it said.

Proceeds will go toward working capital requirements and general corporate purposes. The company previously raised $8.3 million in a private placement in early 2013.

"We are entering an important phase in the strategic transformation of the company, and this transaction provides us with the necessary capital to drive toward profitability," Transgenomic President and CEO Paul Kinnon said in a statement. "We can now focus on commercializing key assets, especially the Ice-Cold-PCR technology, while also improving our competitive position in the molecular diagnostics marketplace."

In January the firm announced it had applied to the Nasdaq to list its shares on the Nasdaq Capital Market. Transgenomic's shares currently trade on the OTC Market. The company also said at the time that it would initiate a one-for-12 reverse stock split.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.